Patients with the acquired immunodeficiency syndrome (AIDS) are characterized by a decrease in the number of T helper cells, a defect that is linked to the impaired immunologic competence. Vitamin A and its dietary precursor, betacarotene, increase absolute T helper cell counts as well as indices of T cell function in both human and animal models. To determine if short-term beta-carotene treatment affects T lymphocyte subsets in patients with AIDS, a single-blind, non-randomized clinical trial of beta-carotene was performed in seven patients with AIDS. Enrollment criteria included no evidence of: a) active opportunistic infection; b) greater than 1 kilogram change in weight in the month preceding enrollment; c) chronic diarrhea or malabsorption; and d) hepatic disease or significant anemia. Beta-carotene was given with meals in two divided doses of 60 mg/day for four weeks; this was followed by no therapy for six weeks. Samples for total white blood cell, lymphocyte and T lymphocyte subset counts were measured at baseline, at the end of four weeks of treatment and another six weeks after treatment had stopped. P24 antigen, beta-2 microglobulin and liver function tests were also measured.
INTRODUCTION
Interest in vitamin A and related compounds to modulate human diseases has expanded in recent years. In children, dietary supplementation with vitamin A reduces mortality due to measles by 60 percent [1] , even without clinical signs of deficiency [1] . In animals, vitamin A deficiency augments mortality due to a variety of infective organisms [2] , and conversely, dietary supplementation enhances survival [2] and lessens morbidity [3] . Although all of the mechanism(s) of vitamin A action are not known on an immunologic aTo whom all correspondence should be addressed: David A. Fryburg [4] as well as indices of T cell function, such as skin graft rejection [5, 6] or mixed lymphocyte response [7] .
Beta-carotene, the major dietary precursor of vitamin A, has similar effects on the immune system. In normal humans, beta-carotene increased OKT4 positive T cells by 40 percent [8, 9] without affecting OKT8 cells. Given these properties of vitamin A and betacarotene, we conducted a preliminary trial of beta-carotene in patients with the acquired immunodeficiency syndrome (AIDS/, which is characterized by impaired immunologic defenses in the setting of a dearth of T helper cells. We chose beta-carotene over vitamin A because of a lower incidence of toxicity [10] . 
METHODS

DISCUSSION
The data from this pilot study suggest that beta-carotene increases the CD4+ cell population in AIDS patients who have greater than 10 cells/pl. The response of the small number of patients in the present study is consistent with that observed in normal adults and related effects of vitamin A in animals, i.e., biologically significant increases in CD4+ cells [4, 8, 9] . Although this study focused on patients with AIDS [11] , three other trials of beta-carotene in HIV-infected patients have recently been reported. Coodley et al. [12] treated HIV-seropositive patients with beta-carotene (180 mg/day in three divided doses) for four weeks. In comparison to placebo, significant fractional increases were observed in their patients, whose helper cell counts ranged from less than 200 to greater than 500/,l. Those [12] and Garewal et al. [13] studied HIVseropositive patients, it is not known if any of the patients had clinical manifestations that characterize AIDS. Bianchi-Santamaria et al. [14] recently treated nine AIDS-related complex (ARC) patients with beta-carotene for six to 21 months. In response to treatment, CD4+ cell counts rose by 11.5 percent, a change that was statistically insignificant. Clinically, however, symptomatic asthenia, feverishness, sweating and diarrhea resolved. None of these patients progressed to AIDS during the six to 21-month observation period.
In spite of the positive response observed in the present study, the CD4+ counts at four weeks were still subnormal. It has been demonstrated, however, that the risks for acquiring different opportunistic infections are related to the absolute helper cell count within the subnormal range [15] . Increases in helper T cell number, therefore, may alter these risks. The lack of response in the more significantly CD4+ depleted group may be due to end-stage immunologic dysfunction or a time-dependent factor, since the short treatment period may not have been long enough to elicit an increase.
Recent observations have suggested that vitamin A deficiency is strongly associated with an increased risk of death in patients with AIDS [16] . In this study of a cohort of drug abusers in Baltimore, along with depressed CD4 counts, serum retinol levels below 1.05 jmollL predicted a four-fold increased risk of death. Moreover, serum retinol [16] or carotene [17] 
